tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Profound Medical Reports Q2 2025 Growth and New Innovations in Prostate Treatment

Story Highlights
Profound Medical Reports Q2 2025 Growth and New Innovations in Prostate Treatment

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Profound Medical ( (TSE:PRN) ) just unveiled an update.

Profound Medical reported its second quarter 2025 financial results, highlighting a 10% sequential growth in procedure volumes for its TULSA-PRO systems. The company is expanding its sales pipeline with 80 new systems in various stages of verification, negotiation, and contracting. The TULSA-PRO system has shown significant improvements in post-operative experiences compared to traditional methods, and the company is set to launch a new TULSA-AI Volume Reduction Module to enhance BPH treatment efficiency. Despite short-term delays in capital sales, the company remains optimistic about its growth prospects and plans to integrate its technology with Siemens Healthineers’ MR scanner by the end of 2025.

The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$12.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.

Spark’s Take on TSE:PRN Stock

According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.

Profound Medical’s stock score reflects the company’s strong revenue growth and strategic potential, balanced by operational inefficiencies and financial challenges. Technical indicators suggest caution due to bearish trends, while valuation remains a concern with negative earnings. Positive earnings call sentiment and future growth prospects are encouraging, yet immediate operational improvements are necessary for sustained success.

To see Spark’s full report on TSE:PRN stock, click here.

More about Profound Medical

Profound Medical Corp. is a commercial-stage medical device company that specializes in developing and marketing AI-powered, incision-free therapies for the ablation of diseased tissue. The company focuses on providing innovative solutions for prostate disease treatment, particularly through their TULSA-PRO system, which is designed to treat prostate cancer and benign prostatic hyperplasia (BPH).

Average Trading Volume: 6,061

Technical Sentiment Signal: Sell

Current Market Cap: C$232M

For a thorough assessment of PRN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1